Key result
Axillary microaxial flow pumps linked to post-MI ventricular septal defect survival.
Why the study?
Does an axillary access microaxial flow pump improve survival compared to a percutaneous microaxial flow pump in patients with post-myocardial infarction ventricular septal defect?
Cohort (n=18)
Does an axillary access microaxial flow pump improve survival compared to a percutaneous microaxial flow pump in patients with post-myocardial infarction ventricular septal defect?
Answers are grounded in this paper and cite their sources.
Initial use of axillary access microaxial flow pumps is associated with significantly higher survival rates compared to percutaneous pumps in patients with post-myocardial infarction ventricular septal defect.
OBJECTIVES: The mortality rate of ventricular septal defect (VSD) following acute myocardial infarction remains high. Mechanical circulatory support devices have been shown to facilitate delayed surgery and improve postoperative survival, although clear guidelines for device selection are lacking. METHODS: This study presents a retrospective cohort analysis of 18 patients with post-infarction VSD treated with microaxial flow pump (mAFP) from March 2017 to November 2024. Patients were divided into 2 groups: the percutaneous group utilized Impella 2.5 or CP (Abiomed, Danvers, MA, USA) and the axillary access group (Impella 5.0 or 5.5). Their clinical outcomes and early to midterm survival rates were analysed. RESULTS: The survival discharge rate was 31% (4 in 13 patients) in the percutaneous group and 100% (5 patients) in the axillary access group, with a significant difference (P = .029). Seven patients who were initially managed with percutaneous mAFP and later required the addition of extracorporeal membrane oxygenation all died perioperatively. The 100-day Kaplan-Meier analysis showed a significant improvement in survival rates in the axillary access group compared to the percutaneous group (log-rank, P = .020). CONCLUSIONS: These findings illustrate variation in surgical timing and device selection and suggest that the early use of an axillary access mAFP may warrant further investigation in post-myocardial infarction VSD patients.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2025) conducted a cohort in Post-myocardial infarction ventricular septal defect (n=18). Axillary access microaxial flow pump (Impella 5.0 or 5.5) vs. Percutaneous microaxial flow pump (Impella 2.5 or CP) was evaluated on Survival discharge rate (p=0.029). Axillary access microaxial flow pumps were associated with a 100% survival discharge rate compared to 31% with percutaneous pumps in post-infarction ventricular septal defect patients.
Synapse has enriched 10 related papers. Consider them for comparative context: